Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

DOI

10.1111/tmi.12784

Type

Journal article

Journal

Trop Med Int Health

Publication Date

12/2016

Volume

21

Pages

1490 - 1495

Keywords

access to medicines, counterfeit medicines, essential medicines, hepatitis C, quality of medicines, substandard medicines, Anilides, Antiviral Agents, Benzimidazoles, Carbamates, Drug Industry, Drug Therapy, Combination, Fees, Pharmaceutical, Fluorenes, Health Services Accessibility, Hepatitis C, Chronic, Humans, Imidazoles, Macrocyclic Compounds, Public Health, Quality Assurance, Health Care, Quality Control, Ritonavir, Simeprevir, Sofosbuvir, Sulfonamides, Uracil, Uridine Monophosphate